Please login to the form below
Former Roche CEO joins BIAL board
Franz Humer to advise Portuguese pharma company
Portugal-based pharma company BIAL has appointed former Roche CEO Franz Humer as a non-executive member of its board.
Humer has vast experience in the pharma industry, spending 10 years as CEO of Swiss giant Roche from 1998 to 2008 and 13 years as chairman of its board of directors from 2001 to 2014 when he retired from the company.
In total he spent 19 years at Roche, where he also served as chief operating officer and head of its pharmaceutical division. This followed 15 years at Glaxo Holdings (now part of GSK) and 8 years at Schering Plough (now part of Merck & Co).
He will now advised BIAL which has a strong presence in southern Europe and in Latin America and is looking to grow internationally.
Luís Portela, chairman of BIAL, said: "It is an honour to count on the experience of Dr Franz Humer, who dedicated his professional career to the pharmaceutical industry in large multinational companies of innovation. His incorporation is especially relevant to BIAL as it is a recognition of the work we have been developing."
COVID-19 Updates and Daily News
Featured jobs
-
Medical Editor
-
Competitive
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
-
Healthcare Lead Copywriter
-
Competitive
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Healthcare Account Director
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
- Nucleus Global announces a trio of promotions
- Moderna cooperating with investigation into possible COVID-19 vaccine allergic reactions
- Pfizer introduces new logo in a ‘shift from commerce to science’
- Valneva set to begin commercial manufacturing of COVID-19 vaccine within days
- Pfizer, BioNTech temporarily slow down shipments of COVID-19 vaccine to EU
- Lilly’s antibody bamlanivimab cuts COVID-19 risk by up to 80%
- Mistrust in medical research: a patient perspective
- Real-world evidence: breaking boundaries in rare disease
- Live Webinar: Importance of Highlighting Patient Voices, Workforce Well-Being, and Health Literacy During and After the Pandemic
- The heavy toll of COVID-19 on cancer patients
- Unpacking rare diseases in the first edition of Delta magazine
- Virtual HealthTech conference powered by Impetus Digital: A Customer Story
PMHub
Nucleus Global
Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...
Latest intelligence
- Mistrust in medical research: a patient perspective
- The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
- Real-world evidence: breaking boundaries in rare disease
- Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...
- The heavy toll of COVID-19 on cancer patients
- We all know that finding and treating cancer early saves lives. During the COVID-19 pandemic, oncology treatments paused while cancer continued to spread. So, what has been the impact of...
Quick links
Infographics
